-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target

Benzinga·04/07/2026 10:05:58
Listen to the news
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.